CO5590933A2 - Composicion y metodo para el tratamiento de la diabetes - Google Patents

Composicion y metodo para el tratamiento de la diabetes

Info

Publication number
CO5590933A2
CO5590933A2 CO04060289A CO04060289A CO5590933A2 CO 5590933 A2 CO5590933 A2 CO 5590933A2 CO 04060289 A CO04060289 A CO 04060289A CO 04060289 A CO04060289 A CO 04060289A CO 5590933 A2 CO5590933 A2 CO 5590933A2
Authority
CO
Colombia
Prior art keywords
nucleotide sequence
regulatory region
detectable product
diabetes
treatment
Prior art date
Application number
CO04060289A
Other languages
English (en)
Inventor
David Taylor-Fishw
Aaron I Vinik
Original Assignee
Gmp Endotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gmp Endotherapeutics Inc filed Critical Gmp Endotherapeutics Inc
Publication of CO5590933A2 publication Critical patent/CO5590933A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4733—Acute pancreatitis-associated protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

1.- Una secuencia de ácido nucleico aislada de la SEQ ID N°: 2).2.- Una secuencia indicadora caracterizada porque comprende:a. una secuencia de nucleótidos que codifica para un producto detectable; yb. una secuencia de nucleótidos de la región reguladora ligada al extremo 5AND#39 de la secuencia de nucleótidos que codifica para un producto detectable, caracterizada porque la secuencia de nucleótidos de la región reguladora comprende una o más regiones seleccionadas de los nucleótidos 1-3137 de la SEQ ID N°: 2).3.- Una secuencia indicadora de conformidad con la reivindicación 3, caracterizada porque además comprende:a. un elemento promotor intercalado entre la secuencia de nucleótidos de la región reguladora y la secuencia de nucleótidos que codifica para el producto detectable.
CO04060289A 2001-10-16 2004-06-25 Composicion y metodo para el tratamiento de la diabetes CO5590933A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32933001P 2001-10-16 2001-10-16

Publications (1)

Publication Number Publication Date
CO5590933A2 true CO5590933A2 (es) 2005-12-30

Family

ID=23284879

Family Applications (2)

Application Number Title Priority Date Filing Date
CO04031543A CO5570658A2 (es) 2001-10-16 2004-04-02 Composicion y metodo para el tratamiento de la diabetes
CO04060289A CO5590933A2 (es) 2001-10-16 2004-06-25 Composicion y metodo para el tratamiento de la diabetes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CO04031543A CO5570658A2 (es) 2001-10-16 2004-04-02 Composicion y metodo para el tratamiento de la diabetes

Country Status (20)

Country Link
US (2) US20040132644A1 (es)
EP (1) EP1435995A2 (es)
JP (1) JP2005506362A (es)
KR (1) KR20050036865A (es)
CN (1) CN1723034A (es)
BR (1) BR0213291A (es)
CA (1) CA2463769A1 (es)
CO (2) CO5570658A2 (es)
CZ (1) CZ2004479A3 (es)
HU (1) HUP0401612A3 (es)
IL (1) IL161073A0 (es)
MA (1) MA27503A1 (es)
MX (1) MXPA04003526A (es)
NO (1) NO20042012L (es)
PE (1) PE20030608A1 (es)
PL (1) PL370069A1 (es)
RU (1) RU2004114865A (es)
SK (1) SK1702004A3 (es)
WO (1) WO2003033808A2 (es)
ZA (1) ZA200402261B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003275853A1 (en) * 2002-10-24 2004-05-13 Mcgill University Use of ingap for reversing diabetes
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
JP2008531730A (ja) * 2005-03-04 2008-08-14 キュアーディーエム、インク． Ｉ型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物
CA2609667C (en) * 2005-05-25 2011-02-22 Curedm, Inc. Human proislet peptide, derivatives and analogs thereof, and methods of using same
EP1840573A1 (en) * 2006-03-27 2007-10-03 Institut Pasteur Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
WO2008064306A2 (en) * 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
BRPI0815308A2 (pt) * 2007-08-30 2016-07-19 Curedm Inc peptídeo das pró-ilhotas de lagerhans, composição farmacûtica, método para estimular na neogêneses das ilhotas ou estimular a regeneração das ilhotas de langerhans e método para tratar uma patologia associada com a função pancreática defeituosa em um indivíduo
AU2013323462A1 (en) * 2012-09-27 2015-04-23 Claresa LEVETAN Generation of new pancreatic beta cells
CN104045702A (zh) * 2013-03-15 2014-09-17 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
CN104045698B (zh) * 2013-03-15 2019-04-16 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
US20160039877A1 (en) * 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
CN104045699A (zh) * 2013-03-15 2014-09-17 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
CN103305457B (zh) * 2013-06-06 2015-07-08 浙江省医学科学院 一种体外扩增胰岛β细胞的方法
US9321812B2 (en) * 2014-03-28 2016-04-26 Perle Bioscience Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
WO2017152861A1 (en) * 2016-03-10 2017-09-14 Shenzhen Hightide Biopharmaceutical, Ltd. Conjugates of islet neogenesis peptides and analogs, and methods thereof
WO2020036918A1 (en) * 2018-08-15 2020-02-20 Wake Forest University Health Sciences Improved formulations for pancreatic islet encapsulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127624A (en) * 1872-06-04 Improvement in apparatus for elevating water
US4658957A (en) * 1985-01-28 1987-04-21 Abbott Laboratories Utility tray
US6106840A (en) * 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5834590A (en) * 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
CA2213610C (en) * 1995-02-22 2013-12-03 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
DK0910571T3 (da) * 1996-05-03 2005-10-31 Abbott Lab Hidtil ukendte antiangiogene peptider, polynucleotider, der koder for samme, samt fremgangsmåder til inhibering af angiogenese
US6090577A (en) * 1997-05-22 2000-07-18 Incyte Pharmaceuticals, Inc. Disease associated acidic protein
US6986994B2 (en) * 2001-01-09 2006-01-17 Gmp Endotherapeutics, Inc. INGAP displacement assays

Also Published As

Publication number Publication date
US20040132644A1 (en) 2004-07-08
SK1702004A3 (sk) 2005-03-04
CA2463769A1 (en) 2003-04-24
PL370069A1 (en) 2005-05-16
MA27503A1 (fr) 2005-09-01
HUP0401612A3 (en) 2006-04-28
CO5570658A2 (es) 2005-10-31
MXPA04003526A (es) 2004-07-22
JP2005506362A (ja) 2005-03-03
RU2004114865A (ru) 2005-05-27
EP1435995A2 (en) 2004-07-14
WO2003033808A3 (en) 2003-09-18
ZA200402261B (en) 2004-09-28
KR20050036865A (ko) 2005-04-20
IL161073A0 (en) 2004-08-31
CZ2004479A3 (cs) 2005-01-12
WO2003033808A2 (en) 2003-04-24
BR0213291A (pt) 2004-10-26
PE20030608A1 (es) 2003-08-26
US20080171704A1 (en) 2008-07-17
CN1723034A (zh) 2006-01-18
HUP0401612A2 (hu) 2004-12-28
NO20042012L (no) 2004-07-16

Similar Documents

Publication Publication Date Title
CO5590933A2 (es) Composicion y metodo para el tratamiento de la diabetes
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
CY1121580T1 (el) ΝΕΟΙ ΠΡΟΑΓΩΓΕΙΣ β-ΑΚΤΙΝΗΣ ΚΑΙ RPS21 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CO5700785A2 (es) Composiciones inmunogenicas novedosas para la prevencion y el tratamiento de enfermedad meningococal
DK289688A (da) Ekspression af proapolipoprotein a-i.
DE69841105D1 (de) Chemokine peptide, varianten, derivate und analoge. ihre verwendung in methode für die hemmung oder erhöhung von einer entzündungsreaktion
DE60318391D1 (de) Bakteriophagen-lysin
ECSP10010082A (es) Udp-glucuronil transferasa y polinucleotido de codificacion
CY1111802T1 (el) Πρωτεϊνη συμμετεχουσα σε αποκατασταση γονιμοτητας φυτου με κυτταροπλασματικη ανδροστειροτητα και γονιδιο που την κωδικοποιει
ECSP11010938A (es) Transferasa glucuronilo y un polinucleótido que codifica el mismo
WO2003048205A3 (fr) Proteines a activite inhibitrice de l'il-6
ATE196926T1 (de) Gen grb3-3, variante und ihre verwendungen
GB9320548D0 (en) Improvements in or relating to organic compounds
WO2002085832A3 (en) Solid mixtures of alpha-hydroxycarbonyl derivatives of alpha-methylstyrene oligomers and their use
ATE414156T1 (de) Lipase-varianten
DK0640098T3 (da) S-gen fra hundecoronavirus og anvendelser deraf
BR0002493A (pt) Processo para a preparação de l-aminoácidos por fermentação e sequências de nucleotìdeos que codificam o gene accda
ATE466082T1 (de) Das nphs2 gen, welches im corticoresistenten nephrotischen syndrome eine rolle spielt
DE60230071D1 (de) Methode für die herstellung von protamin
ES2552598T3 (es) Hemocianina y secuencia de ácido nucleico que codifica para la misma
ES2271040T3 (es) Factores especificos de hifa procedentes de candida albicans.
BRPI0412081A (pt) aptámeros inibidores de catepsina g, uso de aptámeros inibidores de catepsina g, e, composição farmecêutica
SE0101519D0 (sv) Nucleic ACID
WO2001051670A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
BRPI0307873A2 (pt) sequência de nucleotídeo codificado um tolc, que contém uma sequência de aminoácido heteróloga

Legal Events

Date Code Title Description
FA Application withdrawn